🔎 Trials Near Me

Home › Drug Use and Addiction › NCT04939012

Implementation of a Patient-centered, Reproductive Planning Decision Support Tool (MyPath) Among Women With Substance Use Disorder in the Immediate Postpartum Period

Recruiting

Who can join

Ages 18 and older · Women

Full eligibility criteria
Inclusion Criteria

Prenatal Cohort:

* Be greater than or equal to 18 years of age.
* Be pregnant with an EGA of 22 to 37 weeks at enrollment.
* Plan to deliver at research site.
* Meet DSM-5 criteria for a SUD (i.e., opioid, stimulant or other use disorder) and/or have a diagnosis code for a substance use disorder in their medical record.

Postpartum Cohort:

* Be greater than or equal to 18 years of age.
* Be 0-9 days postpartum at enrollment.
* Have delivered at research site.
* Meet DSM-5 criteria for a SUD (i.e., opioid, stimulant or other use disorder) and/or have a diagnosis code for a substance use disorder in their medical record.

Exclusion Criteria:

* Have had a fetal or neonatal death with their current pregnancy.
* Be currently in jail or prison as required by court of law. Persons on probation or in residential facilities do not need to be excluded.
* Have any other condition (social or medical) which, in the opinion of the Investigator, would make study participation unsafe, make study participation difficult, and/or complicate data interpretation.
* PPC ONLY: Documented tubal ligation or hysterectomy procedures at time of delivery hospitalization

About the study

This is a study to determine the effect of a novel patient-centered, reproductive planning decision support tool developed by the research team called MyPath on postpartum contraceptive decision-making among women with SUDs.

What is being tested

Sponsor: University of Pittsburgh · Participants: 400 · Started: Oct 11, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT04939012

Locations in the U.S.

PennsylvaniaMagee Womens Hospital of UPMC, Pittsburgh

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.